

Edgar Filing: Aeterna Zentaris Inc. - Form 6-K

Aeterna Zentaris Inc.
Form 6-K
October 29, 2004

FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

REPORT OF FOREIGN ISSUER

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For the month of October 2004

AETERNA ZENTARIS INC.

(Formerly named AEterna Laboratories Inc.)

1405, boul. du Parc-Technologique
Quebec, Quebec
Canada, G1P 4P5

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40-F.

Form 20-F Form 40-F X
----- -----

Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934

Yes No X
----- -----

If "Yes" is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b): 82-

DOCUMENTS INDEX

DOCUMENTS	DESCRIPTION
-----	-----
1.	Press release dated October 28, 2004 - AEterna Zentaris Announces Third Quarter Financial Results Conference Call and Webcast

Edgar Filing: Aeterna Zentaris Inc. - Form 6-K

[AETERNA ZENTARIS LOGO]

AETERNA ZENTARIS INC. 1405 du Parc-Technologique Blvd.
Quebec (Quebec) Canada G1P 4P5 T 418 652-8525 F 418 652-0881
www.aeternazentaris.com

PRESS RELEASE
For immediate release

AETERNA ZENTARIS ANNOUNCES THIRD QUARTER FINANCIAL RESULTS
CONFERENCE CALL AND WEBCAST

QUEBEC CITY, CANADA, OCTOBER 28, 2004 - AETerna Zentaris Inc. (TSX: AEZ;
Nasdaq: AEZS) announced that its quarterly conference call and webcast have
been scheduled for Thursday, November 4, 2004 at 10:00 a.m. Eastern time. The
call will follow the press release of AETerna Zentaris' third quarter 2004
financial results issued earlier on the same day. Participants may access the
live webcast via the Company's website at www.aeternazentaris.com in the
"investors" section, or by telephone using the following numbers: 416-640-4127,
514-807-8791 or 1-800-814-4941.

A replay of the webcast will also be available on the website for a period of 30
days.

AETerna Zentaris is a biopharmaceutical company with an extensive portfolio of
marketed and development-stage products in oncology, endocrine therapy and
infectious diseases.

-30-

CONTACTS:

MEDIA RELATIONS

Paul Burroughs
(418) 652-8525 ext. 406
paul.burroughs@aeternazentaris.com

INVESTOR RELATIONS

Jacques Raymond
(418) 652-8525 ext. 360
jacques.raymond@aeternazentaris.com

U.S. INVESTOR RELATIONS

Lippert/Heilshorn & Associates
Kim Golodetz
(212) 838-3777
kgolodetz@lhai.com

EUROPE

Matthias Seeber
+49 69 42602 3425
matthias.seeber@zentaris.de

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of

Edgar Filing: Aeterna Zentaris Inc. - Form 6-K

1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AETERNA ZENTARIS INC.

Date: October 28, 2004

By: /s/ Mario Paradis

Mario Paradis
Senior Finance Director and
Corporate Secretary